Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its price objective cut by HC Wainwright from $19.00 to $18.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, StockNews.com began coverage on Oncternal Therapeutics in a research report on Wednesday, August 7th. They set a hold rating on the stock.
Get Our Latest Stock Report on Oncternal Therapeutics
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. During the same period last year, the firm posted ($3.00) earnings per share. On average, sell-side analysts anticipate that Oncternal Therapeutics will post -11.63 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is owned by institutional investors and hedge funds.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Read More
- Five stocks we like better than Oncternal Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Jeff Brown’s Exegesis AI Stock Picks
- What Are Trending Stocks? Trending Stocks Explained
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.